Vancomycin, trimethoprim-sulfamethoxazole, and rifampin

Infect Dis Clin North Am. 1995 Sep;9(3):747-67.


Vancomycin is a safe, effective antibiotic for a variety of serious gram-positive infections. Because of emerging vancomycin-resistant enterococci and the threat of spread of vancomycin-resistant genes to other gram-positive organisms, judicious use of vancomycin should be promoted. Trimethoprim-sulfamethoxazole, a broad-spectrum synergistic combination, continues to find widespread use in gram-negative bacterial infections, especially involving the urinary tract. It has enjoyed enormous success in prophylaxis and therapy of Pneumocystis carinii pneumonia. Rifampin remains of paramount significance as a cidal agent against Mycobacterium tuberculosis; however, increasing reports of strains of MDR-tuberculosis are of great concern.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents / therapeutic use*
  • Anti-Infective Agents, Urinary / therapeutic use*
  • Antibiotics, Antitubercular / therapeutic use*
  • Drug Resistance, Microbial
  • Humans
  • Rifampin / pharmacokinetics
  • Rifampin / pharmacology
  • Rifampin / therapeutic use*
  • Trimethoprim, Sulfamethoxazole Drug Combination / pharmacokinetics
  • Trimethoprim, Sulfamethoxazole Drug Combination / pharmacology
  • Trimethoprim, Sulfamethoxazole Drug Combination / therapeutic use*
  • Vancomycin / pharmacokinetics
  • Vancomycin / pharmacology
  • Vancomycin / therapeutic use*


  • Anti-Bacterial Agents
  • Anti-Infective Agents, Urinary
  • Antibiotics, Antitubercular
  • Vancomycin
  • Trimethoprim, Sulfamethoxazole Drug Combination
  • Rifampin